179 related articles for article (PubMed ID: 9460716)
1. Proliferation and DNA fragmentation in meningioma subtypes.
Maier H; Wanschitz J; Sedivy R; Rössler K; Ofner D; Budka H
Neuropathol Appl Neurobiol; 1997 Dec; 23(6):496-506. PubMed ID: 9460716
[TBL] [Abstract][Full Text] [Related]
2. Intracranial meningeal tumours in childhood: a clinicopathologic study including MIB-1 immunohistochemistry.
Demirtaş E; Erşahin Y; Yilmaz F; Mutluer S; Veral A
Pathol Res Pract; 2000; 196(3):151-8. PubMed ID: 10729919
[TBL] [Abstract][Full Text] [Related]
3. Prognostic significance of MIB-1, p53, and bcl-2 immunoreactivity in meningiomas.
Karamitopoulou E; Perentes E; Tolnay M; Probst A
Hum Pathol; 1998 Feb; 29(2):140-5. PubMed ID: 9490273
[TBL] [Abstract][Full Text] [Related]
4. Triple approach for diagnosis and grading of meningiomas: histology, morphometry of Ki-67/Feulgen stainings, and cytogenetics.
Kolles H; Niedermayer I; Schmitt C; Henn W; Feld R; Steudel WI; Zang KD; Feiden W
Acta Neurochir (Wien); 1995; 137(3-4):174-81. PubMed ID: 8789658
[TBL] [Abstract][Full Text] [Related]
5. Expression of PDGF and its receptor as well as their relationship to proliferating activity and apoptosis of meningiomas in human meningiomas.
Yang SY; Xu GM
J Clin Neurosci; 2001 May; 8 Suppl 1():49-53. PubMed ID: 11386826
[TBL] [Abstract][Full Text] [Related]
6. Malignant meningioma: a clinicopathologic study of 23 patients including MIB1 and p53 immunohistochemistry.
Prayson RA
Am J Clin Pathol; 1996 Jun; 105(6):719-26. PubMed ID: 8659446
[TBL] [Abstract][Full Text] [Related]
7. Prognostic value of proliferation index and expression of the RNA component of human telomerase (hTR) in papillary meningiomas.
Rushing EJ; Colvin SM; Gazdar A; Miura N; White CL; Coimbra C; Burns DK
J Neurooncol; 1999; 45(3):199-207. PubMed ID: 10845390
[TBL] [Abstract][Full Text] [Related]
8. Apoptosis is associated with atypical or malignant change in meningiomas. An in situ labelling and immunohistochemical study.
Ng HK; Chen L
Histopathology; 1998 Jul; 33(1):64-70. PubMed ID: 9726051
[TBL] [Abstract][Full Text] [Related]
9. Histopathological parameters with Ki-67 and bcl-2 in the prognosis of meningiomas according to WHO 2000 classification.
Uzüm N; Ataoğlu GA
Tumori; 2008; 94(3):389-97. PubMed ID: 18705408
[TBL] [Abstract][Full Text] [Related]
10. Involvement of disregulated c-myc but not c-sis/PDGF in atypical and anaplastic meningiomas.
Nagashima G; Aoyagi M; Yamamoto S; Wakimoto H; Tamaki M; Yamamoto K; Fujimoto T; Hirakawa K
Clin Neurol Neurosurg; 2001 Apr; 103(1):13-8. PubMed ID: 11311470
[TBL] [Abstract][Full Text] [Related]
11. Expression of apoptotic and proliferation markers in meningiomas.
Konstantinidou AE; Pavlopoulos PM; Patsouris E; Kaklamanis L; Davaris P
J Pathol; 1998 Nov; 186(3):325-30. PubMed ID: 10211124
[TBL] [Abstract][Full Text] [Related]
12. Apoptotic activity and bcl-2 immunoreactivity in meningiomas. Association with grade and outcome.
Abramovich CM; Prayson RA
Am J Clin Pathol; 2000 Jul; 114(1):84-92. PubMed ID: 10884803
[TBL] [Abstract][Full Text] [Related]
13. Comparative proteomic profiles of meningioma subtypes.
Okamoto H; Li J; Vortmeyer AO; Jaffe H; Lee YS; Gläsker S; Sohn TS; Zeng W; Ikejiri B; Proescholdt MA; Mayer C; Weil RJ; Oldfield EH; Zhuang Z
Cancer Res; 2006 Oct; 66(20):10199-204. PubMed ID: 17047085
[TBL] [Abstract][Full Text] [Related]
14. Expression of BCL-2 oncoprotein on tumor cells and tumor-infiltrating lymphocytes (TIL) in meningiomas.
Roessler K; Dietrich W; Kitz K
Neurosurg Rev; 1999 Dec; 22(4):205-9. PubMed ID: 10682928
[TBL] [Abstract][Full Text] [Related]
15. Topoisomerase II alpha as a reliable proliferation marker in meningiomas.
Roessler K; Gatterbauer B; Kitz K
Neurol Res; 2002 Apr; 24(3):241-3. PubMed ID: 11958416
[TBL] [Abstract][Full Text] [Related]
16. Immunohistochemical study of Ki-67 (MIB-1), p53 protein, p21WAF1, and p27KIP1 expression in benign, atypical, and anaplastic meningiomas.
Amatya VJ; Takeshima Y; Sugiyama K; Kurisu K; Nishisaka T; Fukuhara T; Inai K
Hum Pathol; 2001 Sep; 32(9):970-5. PubMed ID: 11567227
[TBL] [Abstract][Full Text] [Related]
17. Clinical and histopathological analysis of proliferative potentials of recurrent and non-recurrent meningiomas.
Matsuno A; Fujimaki T; Sasaki T; Nagashima T; Ide T; Asai A; Matsuura R; Utsunomiya H; Kirino T
Acta Neuropathol; 1996; 91(5):504-10. PubMed ID: 8740231
[TBL] [Abstract][Full Text] [Related]
18. Correlation between histological grade, MIB-1, p53, and recurrence in 69 completely resected primary intracranial meningiomas with a 6 year mean follow-up.
Lanzafame S; Torrisi A; Barbagallo G; Emmanuele C; Alberio N; Albanese V
Pathol Res Pract; 2000; 196(7):483-8. PubMed ID: 10926326
[TBL] [Abstract][Full Text] [Related]
19. Vascular endothelial growth factor, hepatocyte growth factor/scatter factor, basic fibroblast growth factor, and placenta growth factor in human meningiomas and their relation to angiogenesis and malignancy.
Lamszus K; Lengler U; Schmidt NO; Stavrou D; Ergün S; Westphal M
Neurosurgery; 2000 Apr; 46(4):938-47; discussion 947-8. PubMed ID: 10764269
[TBL] [Abstract][Full Text] [Related]
20. DNA topoisomerase II-alpha and cyclin A immunoexpression in meningiomas and its prognostic significance: an analysis of 263 cases.
Korshunov A; Shishkina L; Golanov A
Arch Pathol Lab Med; 2002 Sep; 126(9):1079-86. PubMed ID: 12204057
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
